https://www.reuters.com/business/healthcare-pharmaceuticals/benefits-moderna-merck-melanoma-vaccine-plus-keytruda-extend-three-years-2023-12-14/ Skip to main content Exclusive news, data and analytics for financial market professionals Learn more aboutRefinitiv Reuters home * World * Business * Markets * Sustainability * Legal * Breakingviews * Technology * Investigations * More My View Register * Healthcare & Pharmaceuticals * Public Health Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years By Michael Erman and Patrick Wingrove December 14, 20233:16 PM UTCUpdated ago * * * * * * * * People pose with syringe with needle in front of displayed Moderna logo Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey [1/2]People pose with syringe with needle in front of displayed Moderna logo in this illustration taken, December 11, 2021. REUTERS/ Dado Ruvic/Illustration/File Photo Acquire Licensing Rights * Companies * Merck & Co Inc Follow * Moderna Inc Follow Dec 14 (Reuters) - An experimental messenger RNA cancer vaccine developed by Moderna (MRNA.O) and Merck & Co (MRK.N) paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time. Moderna shares rose 11% in morning trading after having fallen 50% this year due to waning demand for COVID vaccines and questions about how well its mRNA influenza shot works compared to the current standard and whether the cancer vaccine will be successful. Two analysts said this data was a positive but incremental step. Merck shares fell by 0.6% to $105.70 in morning trading. The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said. The results come at a median point of three years into the study involving 157 patients with stage III/IV melanoma whose tumors were surgically removed before being treated with either the drug/vaccine combination or Keytruda alone with the aim of delaying disease recurrence. A year earlier, the study had shown a 44% reduction of recurrence or death. "The durability of the responses is really strong, they're essentially rock solid through this time," Moderna President Stephen Hoge said in an interview. "This is a pretty significant improvement, a pretty dramatic improvement over standard of care with just Keytruda alone." Morningstar analyst Karen Andersen said the new results could help Moderna and Merck make a case to the U.S. Food and Drug Administration for accelerated approval based on its midstage data. The combination treatment has won U.S. breakthrough therapy and European Medicines Agency PRIME scheme designations, regulatory programs that aim to speed development of innovative treatments. Still, Hoge said that even with the new data it would be some time before the companies can file for approval of the treatment. The vaccine is custom-built based on an analysis of a patient's tumors after surgical removal. The vaccines are designed to train the immune system to recognize and attack specific mutations in cancer cells. Moderna is currently building a dedicated facility in Massachusetts to produce the vaccine at commercial scale, which it hopes to finish sometime next year. "We need to make sure that we have that near completion before we could even contemplate asking for approval," Hoge said. He said the companies are engaging with regulators globally on the pathway for approval for the product. They have already begun a confirmatory late-stage trial for the combination in melanoma, as well as one in non-small cell lung cancer that is already enrolling patients. Reporting by Michael Erman; Editing by Bill Berkrot and Mark Porter Our Standards: The Thomson Reuters Trust Principles. * * * * * Acquire Licensing Rights, opens new tab Read Next * U.S. first lady Jill Biden participates in a U.S. Marine Corps Reserve Toys for Tots event Healthcare & PharmaceuticalscategoryBiden administration to impose inflation penalties on dozens of drugs10:13 PM UTC * Updated ago * An injection pen of Zepbound, Eli Lilly's weight loss drug, is displayed in New York Healthcare & PharmaceuticalscategoryUS employers hire virtual providers as weight-loss drug gatekeepersDecember 13, 2023 * Britain to encourage smokers to swap cigarettes for vapes Future of HealthcategoryBig Tobacco's transition under fire as WHO targets vaping5:11 PM UTC * Illustration shows Pfizer logo Commercial StrategycategoryPfizer shares sink after it resets 2024 COVID expectationsDecember 13, 2023 LSEG Workspace More from Reuters Business * Shopping during the holiday season in New York Luxury slowdown prompts fears of inventory pile-up over key holiday season Retail & Consumercategory * December 14, 2023 * 7:42 AM UTC Early holiday shopping season discounts from high-end fashion retailers like Bergdorf Goodman on New York's Fifth Avenue raised concern that a lacklustre Christmas could lead to inventory gluts - potentially dragging labels into a discounting spiral that would cheapen their image. * An oil pump of IPC Petroleum France is seen at sunset outside Soudron Exploration & ProductioncategoryWorld oil demand next year to rise faster than expected, IEA says4:44 PM UTC * LNG 2023 energy trade show in Vancouver Exploration & ProductioncategoryDiffering LNG outlook stalls Shell talks on gas project with Venezuela -sources4:43 PM UTC * Britain to encourage smokers to swap cigarettes for vapes Future of HealthcategoryBig Tobacco's transition under fire as WHO targets vaping5:11 PM UTC * A Model 3 Tesla vehicle navigates morning rush hour using the car's auto pilot feature in Los Angeles Product LiabilitycategoryTesla recalls nearly all vehicles on US roads over lack of Autopilot safeguards12:21 AM UTC Site Index Browse * World * Business * Markets * Sustainability * Legal * Breakingviews * Technology * Investigations, opens new tab * Sports * Science * Lifestyle About Reuters * About Reuters, opens new tab * Careers, opens new tab * Reuters News Agency, opens new tab * Brand Attribution Guidelines, opens new tab * Reuters Leadership, opens new tab * Reuters Fact Check, opens new tab * Reuters Diversity Report, opens new tab Stay Informed * Download the App (iOS), opens new tab * Download the App (Android), opens new tab * Newsletters, opens new tab Information you can trust Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Follow Us * * * * * Thomson Reuters Products * Westlaw, opens new tab Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. * Onesource, opens new tab The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs. * Checkpoint, opens new tab The industry leader for online information for tax, accounting and finance professionals. LSEG Products * Workspace, opens new tab Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. * Data Catalogue, opens new tab Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. * World-Check, opens new tab Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. * Advertise With Us, opens new tab * Advertising Guidelines, opens new tab * Coupons, opens new tab * Acquire Licensing Rights, opens new tab * Cookies, opens new tab * Terms of Use, opens new tab * Privacy, opens new tab * Digital Accessibility, opens new tab * Corrections, opens new tab * Site Feedback, opens new tab All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. (c) 2023 Reuters. All rights reserved